RecruitingNCT00943514
Immune
Common Variable Immunodeficiency
Also known as CVID, panhypogammaglobulinemia, late-onset antibody deficiency
Common Variable Immunodeficiency is the most prevalent symptomatic primary antibody deficiency, characterized by markedly reduced serum immunoglobulin levels across all major classes and impaired vaccine responses. Affected individuals suff
ORPHA:1572 ↗Gene TNFRSF13BGene TNFRSF13C (variable)Prevalence 1 in 25,000-50,000Onset Late childhood to early adulthood; median diagnosis in 3rd-4th decadePrimary antibody deficiency
13
studies recruiting now
as of 7 Sept 2026
63
studies registered in total
as of 7 Sept 2026
1
countries with a recruiting site
as of 7 Sept 2026
16 May 2025
most recent study posted
among recruiting studies
Recruiting trials
RecruitingNCT00001244
Immune Regulation in Patients With Common Variable Immunodeficiency and Related Inborn Errors of Immunity (IEI)
RecruitingPhase 2NCT06976476
Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia
RecruitingPhase 2NCT02579967
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
RecruitingPhase 2NCT04339777
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 13 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Common Variable Immunodeficiency study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
Registry: USIDNET Registry · Join ↗. Registries connect patients to researchers and often hear about trials first.
About Common Variable Immunodeficiency
Common Variable Immunodeficiency is the most prevalent symptomatic primary antibody deficiency, characterized by markedly reduced serum immunoglobulin levels across all major classes and impaired vaccine responses. Affected individuals suffer recurrent bacterial infections, particularly of the respiratory tract, and are at elevated risk for autoimmune complications, granulomatous disease, and lymphoma. Diagnosis requires exclusion of secondary causes and demonstration of hypogammaglobulinemia persisting beyond age four with documented functional antibody failure.
Common clinical features
Recurrent sinopulmonary bacterial infectionsChronic diarrhea and malabsorptionAutoimmune cytopenias (ITP, AIHA)Splenomegaly and lymphadenopathyGranulomatous lung or liver diseaseIncreased risk of non-Hodgkin lymphomaBronchiectasis from recurrent pneumonias
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Treatments being studied
3 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Phase 3Human Immunoglobulin G (Flebogamma dif (previously flebogammadif))
Phase 2/3Leniolisib Phosphate (Joenja)
Phase 1Apilimod
Before you apply
Things trial teams commonly ask about for Common Variable Immunodeficiency. Not eligibility rules; those are set by each study.
- Trials often require documented IgG below 500 mg/dL and failure of at least two IgG subclasses; confirm current immunoglobulin replacement therapy details before screening
- Autoimmune or granulomatous CVID subtypes may qualify for separate immunomodulatory trial arms — clarify your CVID phenotype with your immunologist
- Prior splenectomy or active malignancy typically disqualifies participants; gather your full surgical and oncology history
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).